- Home
- ZH vs PRTA Comparison
ZH vs PRTA Comparison
Compare ZH & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- PRTA
- Stock Information
- Founded
- ZH 2011
- PRTA 2012
- Country
- ZH China
- PRTA Ireland
- Employees
- ZH N/A
- PRTA N/A
- Industry
- ZH Business Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- PRTA Health Care
- Exchange
- ZH Nasdaq
- PRTA Nasdaq
- Market Cap
- ZH 352.6M
- PRTA 351.5M
- IPO Year
- ZH 2021
- PRTA N/A
- Fundamental
- Price
- ZH $4.51
- PRTA $6.68
- Analyst Decision
- ZH Strong Buy
- PRTA Buy
- Analyst Count
- ZH 1
- PRTA 9
- Target Price
- ZH $4.70
- PRTA $27.67
- AVG Volume (30 Days)
- ZH 318.7K
- PRTA 931.6K
- Earning Date
- ZH 08-21-2025
- PRTA 08-07-2025
- Dividend Yield
- ZH N/A
- PRTA N/A
- EPS Growth
- ZH N/A
- PRTA N/A
- EPS
- ZH N/A
- PRTA N/A
- Revenue
- ZH $464,095,225.00
- PRTA $137,935,000.00
- Revenue This Year
- ZH N/A
- PRTA N/A
- Revenue Next Year
- ZH $7.46
- PRTA $122.02
- P/E Ratio
- ZH N/A
- PRTA N/A
- Revenue Growth
- ZH N/A
- PRTA 54.55
- 52 Week Low
- ZH $3.01
- PRTA $4.32
- 52 Week High
- ZH $6.32
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- ZH 52.60
- PRTA 58.93
- Support Level
- ZH $4.58
- PRTA $6.24
- Resistance Level
- ZH $4.95
- PRTA $6.94
- Average True Range (ATR)
- ZH 0.19
- PRTA 0.28
- MACD
- ZH -0.02
- PRTA 0.04
- Stochastic Oscillator
- ZH 10.20
- PRTA 66.67
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.